2021 CRO Market Size & Growth Projections

Report Overview

Overall, 2020 was not a horrible year for CROs. Yes, we predicted an overall downturn in the market and we are sticking by that based mainly on the hypothesis that the large CROs fared better than the smaller ones. What do the financial numbers tell us? They tell us proposals, RFPs, and contracting were strong in 2020, as witnessed by the impressive growth in backlog. The numbers also tell us that the larger CROs struggled a bit turning the backlog into revenue, which is highly understandable given how much of the healthcare system was under attack in 2020. If first quarter 2021 numbers are any indication, it looks like the future is quite positive for the larger CROs as they work through record-level backlog levels.

Our report provides quantitative analysis into the constant question, “What is the size of the CRO market?” The data within are segmented by phase, geography and service line in order to generate a full picture of the clinical development services market.

We use both data gathered through our syndicated primary market research and publicly available databases to generate this report.

What you will learn:

• Estimated R&D expenditures through 2025
• Projected spending on development, Phase I-IV development, and outsourced Phase I-IV development through 2025, segmented by sponsor type:
  • Large pharma – large molecule
  • Large pharma – small molecule
  • Non-large pharma – large molecule
  • Non-large pharma – small molecule
  • Generic/Specialty
  • Government
  • Private
  • Association/Non-profit
  • Academic
• Spending on CRO services segmented by:
  • Geography
  • Service-line
  • Phase I-IV

Major Topics:

• Overall Market Size and Growth
• 2021 Geographic Assessment
• 2021 Service-line Assessment
• 2021 Development Phase I-IV Assessment
• 2020-2025 CRO Market Model
• 2021 Public CRO Market Share